A5056847094- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Brain Metastases and Treatment
- Chemotherapy-induced cardiotoxicity and mitigation
- Lung Cancer Research Studies
- Cancer and Skin Lesions
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Metastasis and carcinoma case studies
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Radiomics and Machine Learning in Medical Imaging
- Clinical practice guidelines implementation
- Global Cancer Incidence and Screening
- Chemotherapy-related skin toxicity
- Soft tissue tumor case studies
- Cancer, Lipids, and Metabolism
Niigata Cancer Center Hospital
2013-2024
Japan Cancer Society
2023
National Cancer Center Hospital East
2019
Okayama University Hospital
2019
Aichi Cancer Center
2019
Osaka National Hospital
2018-2019
Tokyo National Hospital
2019
St. Marianna University School of Medicine
2019
The Cancer Institute Hospital
2019
Shizuoka General Hospital
2019
Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis previously reported genes significantly associated with metastases the epithelial-mesenchymal transition (EMT) reproducible consistent our dataset. Sixteen pair-matched samples from primary cancers diagnosed collected Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, metastases-,...
// Rin Ogiya 1 , Naoki Niikura Nobue Kumaki 2 Hiroyuki Yasojima 3 Tsutomu Iwasa 4 Chizuko Kanbayashi 5 Risa Oshitanai Michiko Tsuneizumi 6 Ken-ichi Watanabe 7 Akira Matsui 8 Tomomi Fujisawa 9 Shigehira Saji 10 Norikazu Masuda Yutaka Tokuda and Hiroji Iwata 11 Department of Breast Endocrine Surgery, Tokai University School Medicine, Kanagawa, Japan Pathology, Oncology, National Hospital Organization Osaka Hospital, Osaka, Medical Kindai Niigata Cancer Center Niigata, Shizuoka General...
TPS603 Background: Retrospective data suggest breast cancer-specific survival rates with versus without surgery in patients low-grade ductal carcinoma situ (DCIS) are similar. Some DCIS have a low likelihood of progression to invasive cancer, but predicting who is at risk has not been established. Thus, treatment well-balanced / benefit ratio achieved. Four active surveillance clinical trials for commenced the United Kingdom (LORIS), Europe (LORD), States (COMET), and Japan (LORETTA). We aim...
523 Background: The possibility of primary tumor resection (PTR) improving the survival de-novo Stage IV breast cancer (dn-StIV BC) patients has been evaluated by several prospective studies but remains controversial. We designed this phase 3 trial (JCOG1017) comparing with/without dissection after initial systemic therapy based on clinical subtype in dn-StIV BC patients. Methods: Dn-StIV were enrolled first registration. All received therapies according to subtypes. not showing refractory...
Abstract Purpose Mammography screening has increased the detection of subcentimeter breast cancers. The prognosis for estrogen receptor (ER)-positive and human epidermal growth factor 2 (HER2)-negative T1a/bN0M0 cancers is excellent; however, necessity adjuvant endocrine therapy (ET) uncertain. Methods We evaluated effectiveness ET in patients with ER-positive HER2-negative cancer who underwent surgery from 2008 to 2012. Standard was administrated after surgery. primary endpoint cumulative...
Abstract Background Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardiomyopathy (ARCM) in patients with BC remain unclear. We aimed to update our understanding ARCM trastuzumab era. METHODS This retrospective observational cohort study included 2959 treated anthracyclines at three regional centers Niigata City between 1990 2020. Seventy-five (2.5%) developed were categorized into two groups:...
Abstract This article provides updates to readers based on the newly published Japanese Breast Cancer Society Clinical Practice Guidelines for Screening and Diagnosis, 2022 Edition. These guidelines incorporate latest evaluation of evidence from studies diagnostic accuracy. For each clinical question, outcomes benefits harms were established, qualitative or quantitative systematic reviews conducted. Recommendations determined through voting by a multidisciplinary group, documented facilitate...
Abstract Background We conducted a prospective study with the intention to omit surgery for patients ductal carcinoma in situ (DCIS) of breast. aimed identify clinicopathological predictors postoperative upstaging invasive (IDC) preoperatively diagnosed DCIS. Patients and methods retrospectively analyzed DCIS through biopsy between April 1, 2010 December 31, 2014, from 16 institutions. Clinical, radiological, histological variables were collected medical records. Results identified 2,293...
TPS588 Background: The possibility of improving the survival stage IV breast cancer patients by primary tumor resection (PTR) has been reported several retrospective studies; however, these studies essentially suffer from biases such as arbitrary patient selection, diverse timing surgery or various regimens systemic therapy. Five prospective randomized trials including our trial have evaluated efficacy PTR for them. Two final results, but those results were inconsistent. Therefore, this...
Patients with estrogen receptor (ER)-positive breast cancer are less likely to achieve a pathological complete response (pCR) neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than chemotherapy in these hormone-sensitive patients. Most patients ER-positive postmenopausal, and therefore, generally older able tolerate We aimed investigate the efficacy safety of tailored chemoendocrine for postmenopausal Untreated primary invasive ER-positive, HER2-negative, stage...
A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients.Fifty-four patients [ER positive, HER2 negative, T1–2, node metastases (n = 0–3), M0] who had undergone curative resection were enrolled. They receive either TOR 40 mg/day or LET 2.5 therapy. Serum lipids markers measured...
It has been suggested that the biological characteristics of breast cancer may differ among different geographic or ethnic populations. Indeed, triple-negative (TNBC), most lethal subgroup, reported to show a higher incidence in Japan than US. However, genomic studies these tumors are from Western countries and landscape TNBC an Asian population not thoroughly investigated. Here, we sought elucidate diversity by examining actionable driver alterations Japanese patients comparing them with...
Advanced breast cancer patients have a higher risk of postoperative recurrence than early-stage patients. Recurrence is believed to be caused by the increase in micrometases, which were not eradicated preoperative or chemotherapy. Therefore, new therapeutic strategy that can improve treatment efficacy mandatory for advanced cancer. S-1 was shown effective and safe Japanese metastatic treated with previous chemotherapy, including anthracyclines. Thus, this study, we evaluated as adjuvant...
We present the case of a 42-year-old Japanese woman who developed acute heart failure after chemotherapy with epirubicin for breast cancer. Echocardiography revealed cardiac dysfunction left ventricular thrombus. Serial serum troponin T tests were positive over 5-week period, and an endomyocardial biopsy demonstrated ultrastructural lesions which similar to those caused by cardiotoxicities due doxorubicin. Although patient splenic thromboembolism, her function recovered gradually, she...